LBRX Stock — LB Pharmaceuticals Inc Common Stock

LB Pharmaceuticals Inc Common Stock (LBRX)

Updated October 16, 2026.

LBRX is a Stock. Total return is 112.4% over the past 1.1 years, 94.8 points ahead of SPY at 17.6%.

LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for neuropsychiatric conditions including schizophrenia, bipolar depression, and major depressive disorder, with its lead candidate LB-102 currently in Phase 3 trials for acute schizophrenia treatment. The company does not currently have distributions. This security appeals to investors with high risk tolerance seeking exposure to early-stage drug development rather than current income.

LBRX performance versus SPY

Price and return data through 2026-10-16.

Total return is 112.4% over the past 1.1 years, 94.8 points ahead of SPY at 17.6%. Its deepest 1-year drawdown was 31.3%.

LBRX key facts

Asset type

Stock

Asset class

Equity

Inception date

09/11/2025

Distribution frequency

None

Last close

$36.74 (as of 2026-10-16)

Market cap

$1,185,202,090

Average volume

724736.0

Payout ratio

0.0%

P/E ratio

367.4

EPS

$0.10

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

LBRX risks and drawbacks

The deepest 1-year drawdown on record here is 31.3%.

Who may consider LBRX — and who may not

It is a weaker fit for investors who need monthly cash flow (LBRX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on LBRX

• All tickers starting with L

Tagged: Healthcare.

Frequently asked questions